Background: Platinum-containing chemotherapy combinations achieve high response rates in women with advanced ovarian cancer. Unfortunately, most patients need further therapeutic options. Oxaliplatin (L-OHP) is a diaminocyclohexane (DACH) platinum analog active against human and murine cells in vitro and in vivo, including ovarian cells lines, with non-cross resistance characteristics with first (CDDP) and second (CBDCA) generation platinum compounds. The single agent activity of oxaliplatin in 34 consecutive platinum-pretreated ovarian cancer patients, not eligible for other phase II trials, was explored in a compassionate use program framework in a single institution.
Introduction
Salvage chemotherapy after platinum-based treatment of recurrent ovarian carcinoma typically results in low response rates and short survival, with a very small fraction of women with recurrent advanced ovarian cancer surviving beyond two years [1] .
Few alternative treatment options existed till recently for patients who developped progression or recurrence following first-line chemotherapy. However, some prognostic factors that are predictive for therapeutic response to second-line therapy have been identified.
The de novo or acquired pharmacologic resistance to platinum analogs is the most important determinant of prognosis and long term survival of this patient population [2] [3] [4] .
A freedom from progression interval longer than 18 to 24 months with respect to initial treatment corresponds to a higher percentage of therapeutic response and longer survival durations [5, 6] . The relative chemosensitivity of ovarian cancer has been used in the development of new anticancer agents. In the last five years, hexamethymelamine [7] , paclitaxel [8] , docetaxel [9] and topotecan [10] , have been either approved in this indication, or reported to be active, after platinum-based treatment failure.
Diaminocyclohexane platinum (DACH) compounds synthetized 20 years ago [11] seem to have a similar mechanism of cytotoxicity as first and second generation platinum compounds, but their markedly differential in vitro cytotoxic profile has recently led to the proposal of classifying them as a separate family of cytotoxic compounds [12] .
Oxaliplatin is of particular interest, since it is the only DACH platinum currently in clinical phase Il-m development [13] . Its non-cross or partial resistance characteristics with CDDP or CBDCA was demonstrated both in vitro and in vivo in human cancer cell lines [14, 15] , and its interaction with CDDP or CBDCA was shown to be supradditive and synergistic in the same models [16, 17] .
Clinical data have shown that oxaliplatin lacks renal or auditory toxic effects and exhibit minimal hematotoxic effects at recommended doses [18, 19] . Its main side effect is acute, cold-triggered dysesthesias and cumulative neurosensorial toxicity. Its reported activity in ovarian cancer patients within a broad screening phase II experience [13] led us to evaluate its antitumoral activity in a consecutive series of heavily pretreated recurrent ovarian cancer patients without viable therapeutic choices. These patients had either failed or were considered inelegible for simultaneously ongoing phase II studies and were consequently enrolled in a single agent compassionate-use program framework.
Materials and methods

Eligibility criteria
To be eligible for treatment, patients were required to have a pathologically confirmed advanced epithelial ovarian cancer, recurrent after or failing to achieve an objective response to adequately dosed cisplatin and/or carboplatin-based chemotherapy.
Patients with secondary clinical resistance to available platinumbased chemotherapy were also eligible, as were patients who had previously received paclitaxel.
It is noteworthy that poor performance status (PS < 2), borderline renal function (upper normal limit serum creatinine <2.5 x normal (WHO)), previous grade 1-2 (WHO) peripheral neuropathy related to the previous chemotherapy, poor bone marrow reserve secondary to multiple prior chemotherapy lines, often after high dose chemotherapy including CBDCA (with need for hematopoietic growth factor/cellular support), were not considered exclusion criteria from the present program. Indeed, such characteristics made such patients ineligible for formal phase II studies and/or at high risk for agressive salvage chemotherapy combinations.
Patient population
From May 1989 to January 1995, 35 patients seen at the Centre Jean Perrin with advanced ovarian cancer were enrolled in this study. One patient has been considered non-eligible after inclusion, since retrospective evaluation failed to confirm histological proof of epithelial ovarian cancer. This patient is evaluable for toxicity, but excluded from activity assessment analysis.
Patient and disease characteristics are summarized in Table 1 . All patients except one had previously received at least one combination chemotherapy regimen containing cisplatin and/or carboplatin, with a median number of previously administrated chemotherapy regimens of 3 (1-6). Cisplatin had been previously administered to 33 patients with a median cumulative dose of 536 mg/sqm (range: 94-1085). Carboplatin had been previously given to 27 patients with a median cumulative dose of 1177 mg/sqm (range 174-2765), and was part of high-dose chemotherapy regimens (with autologous bone marrow transplantation) in six of them. Taxanes (paclitaxel) had previously been given to five patients, none of them achieving an objective response to such treatment.
Twenty-one patients had documented platinum refractory disease according to Markman's criteria [5] , that is failure to respond to treatment or disease progression within six months after discontinuation following a response. Ten patients were classified as primary, and 11 as secondary resistant, while 13 patients were potentially sensitive to platinum therapy.
Thirty-two of 34 ovarian cancer patients had macroscopically measurable and/or evaluable disease. In the two other patients with known peritoneal disease, an increase of CA 125 serum level had accurately reflected previously progressive disease, and the antitumoral activity of oxaliplatin could be assessed solely by the marker's evolution.
The majority of patients had bulky tumor masses, with multiple sites of disease at treatment initiation (Table 1) .
Toxicity and activity assessment
The toxicity was graded according to WHO criteria. Assesment of antitumor response was performed at each treatment cycle by a physical examination and a serum CA 125 determination, and every two-three cycles by CT scan and/or echosonography. Responses were defined according to WHO guidelines as follows: CR was defined as the complete disappearance of all detectable malignant disease for at least four weeks. PR was defined as a >50% decrease in the sum of the products of the diameters of measurable lesions for at least four weeks. No simultaneous increase in the size of any lesion * Markmann criteria [5] .
or tumor marker , or appearance of any new lesion could occur. SD was defined as less than 25% change in measurable disease with the absence of new lesions. Progressive disease (PD) was defined as an increase of >25% in the size of a measurable lesion or the appearence of an unequivocal new lesion. Duration of response was determined by the interval between the first day on treatment and the first date disease progression was objectively documented. The survival was calculated from the beginning of the treatment until the death. All major responses were reviewed by a panel that consisted of a reference radiologist (H.C.) and a medical oncologist (E.C.) external to the institution.
Treatment and follow-up
Before therapy, all patients had a complete medical history and underwent a physical examination. Baseline laboratory studies included complete blood cell count/platelets, serum chemistries and CA 125 determination. While CBC were done weekly while on treatment, CA 125 and LFTs were repeated every cycle. Imaging assessment was done every two-three cycles. Other imaging and specialized tests were performed only if clinically indicated.
Oxaliplatin was provided on an individual request, compassionate-use basis by Debiopharm (Lausanne/Switzerland). It was diluted in 500 ml of 5% dextrose and infused over 20 minutes (28 patients) or 2 hours (seven patients), every three to four weeks.
The initial phase I trial by Mathe et al. with intrapatient dose escalation, had a minimally active dose as recommended dosage endpoint [20) established as 67-90 mg/m 2 q 3 weeks given as a slow bolus (15'-20" ). An orthodox phase I trial by Extra et al. [19] defined the recommended dose as 130 mg/m 2 q 3 weeks given as a 2-hour i.v. infusion [19] . Lower starting doses (<90 mg/m 2 ) were used in the first patients of the present series, but once the safety and tolerance were established at higher dose levels, the starting dose was increased. There were five patients treated at the dose range of 58-89 mg/m 2 /cycle, 24 patients received 90-100 mg/m 2 /cycle, and 6 patients were treated with 120-130 mg/m 2 /cycle. Minor (<10%) empirical dose adjustments were done occasionally, according to peripheral neuropathy, renal function and/or subjectively estimated bone marrow reserve resulting from previous cisplatin and/or carboplatin based treatments.
Antiemetic prophylactic treatment consisted in anti HT3 often supplemented with steroids, with rare instances of associated metocloparmide and benzodiazepines.
Results
Toxicity
Thirty-five patients received 222 cycles of oxaliplatin with a median number of cycles per patient of 5 (range 1-27) and a median total oxaliplatin dose of 424 mg/ sqm (range 125-1911).
All patients and treatment cycles were evaluable for toxicity, except one patient lost to follow-up after a single oxaliplatin administration. Table 2 lists the maximum toxicity grades per cycle and per patient.
Myelosuppression was mild to moderate, without grade 3-4 leukoneutropenia, despite previous ABMT including high-dose CBDCA in 6 (17%) of patients.
Grade 3-4 anemia and thrombocytopenia were seen in 3% and 1.5% of cycles, respectively, clustered in the six patients mentioned above.
Grade 3 diarrhea was seen in 9% of patients and 3% of cycles, without grade 4 episodes.
The clinical profile of oxaliplatin neurotoxicity, as reported in phase I-II studies, has already been described [19] .
Oxaliplatin related acute dysesthesias were observed in most of patients (82% of cycles and 79% of patients). These accral symptoms (hands, feet and perioral area) began within a few hours after the end of the infusion and were mild (61% of patients, 71% of cycles) or moderate (15% of patients, 10% of cycles) in the majority of cases. They were transient, lasting a few minutes, but they could reappear (rarely) again the next day or over the following week, mainly triggered by exposure to cold.
The only grade 3 neurosensory toxicity seen concerned one patient with a grade 2 baseline neuropathy status. Seven patients had a grade 1 (WHO) baseline neuropathy, with no increase of this toxicity under therapy by oxaliplatin. Although, prior to treatment, seven patients had presented a residual grade 1 renal function (WHO), no renal toxicity was observed during or after oxaliplatin treatment.
Activity
Thirty-four pretreated, progressing on treatment, ovarian cancer patients entered the trial (32 with measurable/evaluable disease). Twenty-nine of them were assessable for antitumoral activity. The causes for nonevaluability were treatment and follow-up refusal after one cycle in three patients, while two patients had nonmeasurable/evaluable disease, except elevated serum CA 125 levels (255 x and 490 x fold upper normal value limits).
There were nine objective responses, all of them partial, for an ORR of 29% in evaluable patients, and 26.5% when calculated for all 34 eligible patients. Eight patients were assessed as disease stabilization, including the two patients with exclusive CA 125 marker decrease as sole tumoral status gauge.
Thirty patients had baseline CA 125 elevation (5*2 x normal upper value -range 2-800 x Nl).
Six of seven objective responders with abnormally elevated baseline CA 125 had a corroborating decrease, one of them remaining stable. Amongst the seven disease stabilizations with elevated markers base- (83) 29 (19) 35 (21) 50 (36) 6 (45) 17 (17) 9 (11) 17 (7) 15 (5) 17 (7) 9(3) 35 (14) 3 ( line CA125, four had a ^ 50% decrease in CA125 (including the two patients with the marker as the sole disease indication), the remaining three having marker stabilization. Antitumoral objective activity was analysed according to clinical platinum resistance status (Markman's criteria) [5] (Table 3) : there were six responses among thirteen potentially sensitive patients (46%) while three of 18 platinum refractory evaluable patients also experienced an objective response (3/18 -17%). One response was observed among the three evaluable paclitaxel refractory patients. When looking at evidence of objective response by site, there were 5/13 tumoral lymph nodes, 5/26 abdominopelvic localizations, and 1/6 hepatic metastases assessed as responding.
By initial oxaliplatin dose level, there was one PR in the five patients treated in the 58-89 mg/m 2 /cycle range, eight PR amongst the 23 eligible patients treated in the 90-100 mg/m 2 /cycle range, and no responses seen in the three evaluable patients treated at 120-130 mg/m 2 /cycle. Amongst the nine objective responders to oxaliplatin, three had failed to respond (1 PD, 2 SD) to the last previous cisplatin/carboplatdn based chemotherapy while five had responded to it (4 CR, 1 PR), the information being unavailable in the remaining one.
As of April 1996, nine patients are alive. The median survival of the whole cohort is 12 months (range 2-54+).
Discussion
Ovarian cancer patients with previous multiple recurrences may respond to a number of second-line chemotherapeutic treatments [21] , including cisplatin and carboplatin [22, 23] . The aim of single agent salvage chemotherapy in this setting remains palliative, with quality-of-life preservation or improvement constituting a major goal [22] .
The efforts to overcome clinical failure and drug resistance of platinum species had mainly focused on dose intensification [23] [24] [25] . In patients whose relapsing disease was treated with carboplatin alone at standard doses (300-400 mg/sqm), no response was seen in patients resistant to cisplatin, while some activity was confirmed in cases of late relapses (>12 months) [25] . An absence of response was seen in patients for whom first-line treatment with cisplatin or carboplatin-containing regimens had also failed. A major factor of response likelihood to salvage chemotherapy in ovarian cancer is the progression-free interval after primary therapy [5] .
In the past decade, there has been a focus in the search for new active drugs in ovarian cancer, particulary agents without cross-resistance with available platinum derivates. It is important to establish the order of clinical evidence of non cross-resistance between chemotherapeutical agents, since this may help to design more effective regimens. The development of new platinum compounds with putative non cross-resistance to cisplatin has flourished in the last decade. The DACH family, of interest for its limited partial cross-resistance to cisplatin, has provided two compounds reaching clinical development. Trials with tetraplatin were stopped after a prohibitive neurotoxicity was observed during phase I [26] . Oxaliplatin, synthetised by Kidani, has demonstrated a non cross-resistance with cisplatin or carboplatin both in vitro and in vivo in human cell lines [14, 15] . Evidence of oxaliplatin clinical activity in cisplatin-resistant ovarian cancer has been previously reported by Misset et al. [13] . This differs significantly from carboplatin, iproplatin, zeniplatin and lobaplatin, all of which demonstrated clinical cross-resistance with cisplatin [25, [28] [29] [30] [31] .
Our reported L-OHP/CDDP (biplatin) experience supports the preclinically perceived synergistic cytotoxic effect between cisplatin and oxaliplatin [32] , while also showing the potential feasibility for oxaliplatincontaining multiple drug combinations, the latter being partially motivated by the present report's data.
Although the monocentric compassionate use experience we report is by no means a formal phase II study, the present data validate oxaliplatin as an active single agent in heavily pretreated ovarian cancer patients. Indeed, most patients were treated below the currently recommended dose of 130 mg/sqm q3 weeks, recently approved in France for the treatment of pretreaded 5-fluorouracil refractory colorectal cancer patients [33] . Most patients in this cohort were not eligible for, or had failed, simultaneously ongoing phase II trials with paclitaxel. The reasons for ineligjbility were linked to the number of previous chemotherapy lines, to borderline major organ function and/ or poor bone marrow reserve.
After an external response review, the objective response rate was 29% (31% in evaluable patients) (CI 95%: 15-50), with 19% disease stabilizations. Our data confirm that oxaliplatin has clinical non-cross resistance characteristics in a substantial proportion of patients with cisplatin refractory disease at hematologically subtoxic levels. Moroever, oxaliplatin's favorable therapeutic index makes it particulary attractive combinations chemotherapy.
The issue of oxaliplatin's single agent activity in platinum refractory ovarian cancer is being clarified by two ongoing trials. The first, a French phase II study at the recommended-dose of 130 mg/sqm x q 3 weeks, has eligibility criteria based on clinical resistance to cisplatiri and/or carboplatin. The second, a randomized phase n/IH study between paclitaxel (175 mg/sqm) and oxaliplatin (130 mg/sqm), is presently conducted by the EORTC Gynecologic Group, also limited to patients having progressed while on or within 12 months of cisplatin-and/or carboplatin-based treatment.
We consider our data encouraging. While awaiting verification through further phase II studies, they suggest the need to furter explore the role of oxaliplatin in first-line therapy for the treatment of advanced ovarian cancer.
